ag-1296 has been researched along with von Hippel-Lindau Disease in 1 studies
6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase
von Hippel-Lindau Disease: An autosomal dominant disorder caused by mutations in a tumor suppressor gene. This syndrome is characterized by abnormal growth of small blood vessels leading to a host of neoplasms. They include HEMANGIOBLASTOMA in the RETINA; CEREBELLUM; and SPINAL CORD; PHEOCHROMOCYTOMA; pancreatic tumors; and renal cell carcinoma (see CARCINOMA, RENAL CELL). Common clinical signs include HYPERTENSION and neurological dysfunctions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Paulsen, N | 1 |
| Brychzy, A | 1 |
| Fournier, MC | 1 |
| Klausner, RD | 1 |
| Gnarra, JR | 1 |
| Pause, A | 1 |
| Lee, S | 1 |
1 other study available for ag-1296 and von Hippel-Lindau Disease
| Article | Year |
|---|---|
Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.
Topics: Adenocarcinoma, Clear Cell; Cell Division; Cell Hypoxia; Enzyme Inhibitors; ErbB Receptors; Gene Exp | 2001 |